Investor Relations

Investor Relations

Company Overview

CollPlant is a regenerative medicine company focused on 3D bioprinting of tissues and organs, and on developing and commercializing tissue repair products for orthobiologics, and advanced wound care markets. Our products are based on our rhCollagen (recombinant human collagen) that is produced with CollPlant's proprietary plant based genetic engineering technology.

Our products address indications for diverse fields of organ and tissue repair, and are ushering in a new era in regenerative medicine. Our flagship rhCollagen BioInk product line is ideal for 3D bioprinting of tissues and organs, and our unique Vergenix line of rhCollagen products includes a soft tissue repair matrix for treating tendinopathy and a wound repair matrix to promote a rapid optimal healing of acute and chronic wounds.

Corporate Presentation

Corporate Presentation

Download Corporate Presentation

Stock Information

Latest Financial Results

Q3 2018

Quarter Ended Sep 30, 2018

Latest Annual Filing

Fiscal Year Ended Dec 31, 2017

View Filing

Investor Contact Information

Company

CollPlant Holdings Ltd.
3 Sapir Street
Weizmann Science Park
Ness Ziona 74140
Israel

Investor Relations

Eran Rotem
Deputy CEO & CFO
T: +972 (73) 2325612
F: +972 (73) 2325602
eran@collplant.com

Corporate Profile®
Laurel Moody
1185 Avenue of the Americas 3rd Floor
New York, NY 10036
T: +1 212 931 8787 Ext 101

Cybele Holdings Ltd.
Yael Schnitzer
T: +972(3)5755123
yael@cybele.co.il

Transfer Agent

The Bank of New York Mellon
Depositary Receipts Division - Global Client Solutions
Arlene C. Villareal
Vice President
101 Barclay Street, 22W
New York, NY 10286
T: 212-815-8162
Arlene.villareal@bnymellon.com

® 2018 CollPlant Ltd. All rights reserved. Version: CPW 02-16

Market Data copyright © 2018 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.